Direkt zum Inhalt
Merck

Islet O-GlcNAcylation Is Required for Lipid Potentiation of Insulin Secretion through SERCA2.

Cell reports (2020-05-07)
Amber Lockridge, Seokwon Jo, Eric Gustafson, Niklas Damberg, Ramkumar Mohan, Miranda Olson, Juan E Abrahante, Emilyn U Alejandro
ZUSAMMENFASSUNG

During early obesity, pancreatic β cells compensate for increased metabolic demand through a transient phase of insulin hypersecretion that stabilizes blood glucose and forestalls diabetic progression. We find evidence that β cell O-GlcNAcylation, a nutrient-responsive post-translational protein modification regulated by O-GlcNAc transferase (OGT), is critical for coupling hyperlipidemia to β cell functional adaptation during this compensatory prediabetic phase. In mice, islet O-GlcNAcylation rises and falls in tandem with the timeline of secretory potentiation during high-fat feeding while genetic models of β-cell-specific OGT loss abolish hyperinsulinemic responses to lipids, in vivo and in vitro. We identify the endoplasmic reticulum (ER) Ca2+ ATPase SERCA2 as a β cell O-GlcNAcylated protein in mice and humans that is able to rescue palmitate-stimulated insulin secretion through pharmacological activation. This study reveals an important physiological role for β cell O-GlcNAcylation in sensing and responding to obesity, with therapeutic implications for managing the relationship between type 2 diabetes and its most common risk factor.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
Diazoxid